drugset
Drugs / PfCP2.9
last change Jan 2006 re-read 9 days ago

PfCP2.9

also known as AMA-1/MSP-1 Recombinant Malaria Vaccine

Vaccine

Developed for
Plasmodium falciparum malaria
Investigated by
PATH · Second Military Medical University · Shanghai Wanxing Bio-Pharmaceutical Co. Ltd. · World Health Organization · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Trials 1

today NCT00284973 · Ph 1
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00284973 Jan 2006 → ? Plasmodium falciparum malaria Shanghai Wanxing Bio-Pharmaceutical Co. Ltd. Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as PfCp2.9 “This is a double blind, randomized, controlled Phase I study of PfCp2.9, an experimental malaria vaccine candidate, adjuvanted with Montanide ISA 720.” NCT00284973 ↗
1

“one malaria vaccine candidate, PfCP2.9 adjuvanted with Montanide ISA 720” NCT00284973 ↗
Known as AMA-1/MSP-1 Recombinant Malaria Vaccine “Ph-1 Double-Blind Randomized Control Study-Evaluate Safety & Immunogenicity of Wanxing Bio-Pharmaceuticals AMA-1/MSP-1 Recombinant Malaria Vaccine (PfCP-2.9) Adj. w/ Montanide...” NCT00284973 ↗
Modality Vaccine “one malaria vaccine candidate, PfCP2.9 adjuvanted with Montanide ISA 720” NCT00284973 ↗